ABSTRACT Knowledge of chronic obstructive pulmonary disease (COPD) as a common, preventable and treatable condition has advanced in the last two decades, as evidenced by the increase in scientific literature. Tobacco smoking still remains a predominant risk factor for COPD. Thus smoking cessation management should be obligatory in every case. Although spirometry is integral to the diagnosis of COPD, one should also be aware of its limitations. COPD is a chronic disease associated with comorbidities that define its extrapulmonary manifestations. Systemic inflammation provides the biological link, while exacerbations play a prominent role in the current approach to disease evaluation. This paper reviews the latest Global Initiative for Chronic Obstructive Pulmonary Disease revision, focusing on the paradigm shift in assessment that would directly influence therapeutic decisions. Also discussed are the newer drugs and combinations of existing inhaler therapies that now present clinicians with more options, as well as bronchoscopic interventions that may perhaps offer a lower-morbidity alternative than surgical lung volume reduction. Finally, this review highlights how integrated care models can bridge the gap between components and complete a comprehensive sphere of COPD care.
I NTRO D U C TIO N
Chronic obstructive pulmonary disease (COPD) is starting to receive the attention that has eluded it for the last century, with more scientific research conducted and published in the last 20 years than in all of its known history combined. This came about partly from the concerted efforts of the Global Initiative for Chronic Obstructive Lung Diseases (GOLD), a collaborative effort among the United States' National Heart, Lung, and Blood Institute, National Institutes of Health and World Health Organization. Since 1997, GOLD committees have worked with healthcare professionals and public health officials around the world to raise awareness of COPD, as well as to improve its prevention and treatment. (1) The affliction that we now recognise as COPD was thought to be first described in 1837 by Laënnec, the inventor of the stethoscope. Noting that the postmortem lungs of sufferers were hyperinflated, Laënnec deduced that "the chief reason of this affection having been so completely overlooked is that it is in some sort merely the exaggeration of the natural condition of the viscus." In an era where cigarette smoking was rare, the finding correlated with asthma, which was considered a 'nervous' condition then. (2) It was not until 1966 that a new name for an old malady, encompassing chronic bronchitis, asthmatic bronchitis and emphysema, came to be included under the rubric 'chronic obstructive pulmonary disease', which became widely adopted.
Fast-forwarding to this millennium, COPD is still a largely underappreciated medical condition. At least half of all patients with COPD in the United States are undiagnosed. (4) Even when diagnosed, undertreatment is prevalent, with 30%-70% of diagnosed individuals receiving either no treatment or suboptimal treatment. (5, 6) In spite of the potential under-detection, as of 2011, COPD was the 7th and 8th most common cause of hospitalisation and mortality, respectively, in Singapore.
SMOKER'S DISEASE OR DISEASED SMOKER?
With smoking proven to be strongly associated with a decline in lung function, as reported in the classic paper by Fletcher and Peto, (8) the aetiology of COPD was mainly attributed to tobacco exposure until recently. Evidence of nonsmoking COPD occurs with a wide variation in prevalence and is reported in at least one out of four diagnosed patients, with a much higher degree of disease burden than previously believed. (9) Risk factors for COPD in nonsmokers may include genetic factors, longstanding asthma, outdoor air pollution (from traffic and other sources), environmental tobacco smoke exposure, biomass smoke exposure, occupational smoke exposure, diet, recurrent respiratory infection in early childhood and tuberculosis. (10) Nonsmoking COPD is a neglected entity typically excluded in clinical trials, with a lack of characterisation of its profile. 
O B S T R U C T I V E B U T N O T F U L LY R E V E R S I B L E ?
In the most recent revision of the GOLD guidelines in 2011, spirometry was made a requirement to confirm the clinical diagnosis of COPD, further emphasising the importance of this test modality. The use of spirometry prevents misdiagnosis and ensures proper evaluation of the severity of airflow limitation. (13) However, access to reliable spirometry continues to be lacking in many countries, resulting in the underdiagnosis of COPD in these countries. In a 2012 worldwide survey on early COPD diagnosis, the most frequently cited priority was the need to improve the use of spirometry in primary care. (14) Diagnosing COPD without a spirometer reading may be comparable to an attempt to detect hypertension without a sphygmomanometer blood pressure reading. The traditional teaching that bronchodilators do not significantly reverse airflow obstruction in COPD is no longer thought to reflect the true nature of diseased airways. Many COPD patients fulfill these spirometric criteria for bronchodilator response, whereas some asthmatics do not (i.e.
irreversible asthma). This has led to a change in the description of COPD to that of an airway disease that is not fully reversible.
In fact, GOLD has removed the reversibility description from its definition of COPD. In essence, the diagnosis of airflow obstruction using a decreased FEV 1 /FVC ratio of less than 0.70 is more essential, with only post-bronchodilator FEV 1 needed to classify severity of airflow limitation, without the need for gauging the presence or absence of a bronchodilator response.
With this imperfection in mind, some experts have suggested the use of CT examinations (14) to provide a useful measure of the presence and extent of emphysema, airway disease, and more recently, pulmonary vascular disease for clinical correlation. CT, however, will not detect chronic bronchitic COPD in a patient without emphysema, and thus its overall utility requires further study. In smokers, emphysema distribution on CT has been shown to be associated with BMI, FEV 1 , severity of dyspnoea and prognostic index (i.e. BODE [BMI, airflow obstruction, dyspnoea and exercise capacity] index). 
A PA R A D I G M S H I F T I N G O LD
This review is incomplete without comment on the 2011 GOLD revision (13) and the recent 2013 update. Test score (27) has a direct impact on therapeutic decisions. This, together with the evaluation of airflow obstruction grade with and clinical benefits. However, after many years, the role of ICS in COPD is still debatable. Nonetheless, the landmark threeyear TORCH (TOwards a Revolution in COPD Health) study (29) has shown that although there was no significant reduction in death from all causes in ICS-LABA treated patients, there was a reduction in the annual rate of exacerbations, as well as improved health status and spirometric values. Of note, although there was no difference in the incidence of ocular or bone side effects, ICS-treated patients had a higher probability of contracting pneumonia. However, the clinical significance of ICS-related pneumonia is still disputed. (30) (31) (32) Roflumilast, a new oral phosphodiesterase-4 inhibitor, is an antiinflammatory drug approved for use in moderate to severe COPD patients with symptoms of chronic bronchitis and frequent exacerbations. This subset of COPD patients benefitted most in terms of lung function, symptom improvement and lower exacerbation rates; (33, 34) however, treated patients showed small, but significant, weight loss and gastrointestinal effects.
In 2003, the National Emphysema Treatment Trial (NETT) (35) proved that in a highly selected group of COPD patients (upper lobe emphysema with low exercise capacity), a survival advantage could be gained by lung volume reduction surgery.
This surgery, however, carried significant morbidity of prolonged postoperative air-leaks and hospitalisation, (36) 
CO N CLU S IO N
COPD is now more prevalent than before. There is a greater appreciation of the challenges of smoking cessation and nicotine dependence. Worldwide, the non-smoking population of COPD is getting more attention. Although spirometry is required to confirm COPD, early disease cannot be detected concept assimilating best practices and innovating models of patient support, patients with COPD should no longer accept a nihilistic attitude from caregivers.
